Although the past two decades have produced exciting discoveries in the genetics and
pathology of amyotrophic lateral sclerosis (ALS), progress in developing an effective therapy …

Disease heterogeneity in amyotrophic lateral sclerosis poses a substantial challenge in drug
development. Categorization based on clinical features alone can help us predict the …

The description of group-level, genotype-and phenotype-associated imaging traits is
academically important, but the practical demands of clinical neurology centre on the …

Motor neuron disease is an umbrella term encompassing a multitude of clinically
heterogeneous phenotypes. The early and accurate categorisation of patients is hugely …

The thalamus is a key cerebral hub relaying a multitude of corticoefferent and corticoafferent
connections and mediating distinct extrapyramidal, sensory, cognitive and behavioural …

Amyotrophic lateral sclerosis (ALS) is associated with considerable clinical heterogeneity
spanning from diverse disability profiles, differences in UMN/LMN involvement, divergent …

Background Brainstem pathology is a hallmark feature of ALS, yet most imaging studies
focus on cortical grey matter alterations and internal capsule white matter pathology …

Background: Magnetic resonance spectroscopy (MRS) in amyotrophic lateral sclerosis
(ALS) has been overwhelmingly applied to motor regions to date and our understanding of …

Frontotemporal involvement has been extensively investigated in amyotrophic lateral
sclerosis (ALS) but remains relatively poorly characterized in other motor neuron disease …

Background Primary lateral sclerosis (PLS) is a low incidence motor neuron disease which
carries a markedly better prognosis than amyotrophic lateral sclerosis (ALS). Despite …